Pfizer Inc. and GlaxoSmithKline PLC recently reached an agreement to form a consumer healthcare joint venture, expected to be finalized during the second half of 2019. The deal addresses many of the issues that have plagued both pharma giants in regards to their consumer healthcare businesses, and each company is banking on the JV to boost sagging investor confidence. Tap into the details of this all-equity deal, which gives GSK 68% control over operating management, in this data-packed article from HBW Insight.
R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking
- Newsletter
- 3 Pages
- Global